exenatide-XTEN (VRS-859) / Aravive  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
exenatide-XTEN (VRS-859) / Aravive
ACTRN12610000839000: A Phase 1, single dose, dose-ascending study of VRS-859, to observe the safety, tolerability and effect in Patients with Type 2 Diabetes Mellitus

Completed
1
15
 
Versartis Inc., Versartis Inc.
Type 2 Diabetes Mellitus
 
 

Download Options